Table 3.
Comparison of PC1/2 between patients with WT and a pfk13 NS-mutation in Asia. Metric is the fold increase of PC1/2 in mutants vs. wild type. Only mutations with n ≥ 5 are shown. With only two exceptions (K189T and K438N), all patients that carried parasites with the indicated pfk13 mutant codon showed a PC1/2 significantly different from those that carried WT parasites
| Comparison of PC1/2 | ||||||||
|---|---|---|---|---|---|---|---|---|
| N with | N with | Univariable | Multivariable1 | |||||
| Codon | mutation | WT | xPC1/2 | 95%CI | p value | xPC1/2 | 95% CI | p value |
| K189T | 8 | 148 | 1.1 | 0.8–1.4 | 0.729 | 1.1 | 0.8–1.4 | 0.644 |
| E252Q | 114 | 589 | 1.5 | 1.4–1.6 | < 0.001 | 1.5 | 1.4–1.6 | < 0.001 |
| K438N | 10 | 386 | 0.9 | 0.7–1.1 | 0.251 | 0.9 | 0.7–1.1 | 0.237 |
| P441L | 53 | 565 | 2.1 | 1.9–2.3 | < 0.001 | 2.2 | 2.0–2.4 | < 0.001 |
| F446I | 79 | 303 | 1.6 | 1.4–1.7 | < 0.001 | 1.5 | 1.4–1.7 | < 0.001 |
| G449A | 6 | 41 | 1.9 | 1.4–2.6 | < 0.001 | 1.9 | 1.3–2.7 | < 0.001 |
| N458Y | 34 | 520 | 2.5 | 2.2–2.8 | < 0.001 | 2.5 | 2.2–2.8 | < 0.001 |
| M476I | 8 | 481 | 2 | 1.6–2.5 | < 0.001 | 2.0 | 1.5–2.5 | < 0.001 |
| A481V | 5 | 410 | 1.8 | 1.3–2.4 | < 0.001 | 1.6 | 1.2–2.2 | 0.002 |
| Y493H | 33 | 313 | 2.6 | 2.2–3.0 | < 0.001 | 2.7 | 2.3–3.1 | < 0.001 |
| R515K | 5 | 352 | 1.9 | 1.4–2.6 | < 0.001 | 2.0 | 1.5–2.7 | < 0.001 |
| P527H/L* | 23 | 422 | 1.7 | 1.5-2.0 | < 0.001 | 1.7 | 1.5–2.0 | < 0.001 |
| N537I | 8 | 231 | 1.7 | 1.3–2.2 | < 0.001 | 1.8 | 1.4–2.3 | < 0.001 |
| G538V | 24 | 558 | 1.8 | 1.6–2.1 | < 0.001 | 1.9 | 1.6–2.2 | < 0.001 |
| R539T | 76 | 369 | 2.1 | 1.9–2.4 | < 0.001 | 2.1 | 1.9–2.4 | < 0.001 |
| I543T | 92 | 156 | 1.9 | 1.7–2.3 | < 0.001 | 2.1 | 1.8–2.4 | < 0.001 |
| I543T** | 27 | 140 | 2.8 | 2.3–3.4 | < 0.001 | 2.8 | 2.3–3.5 | < 0.001 |
| P553L | 16 | 529 | 2.2 | 1.8–2.6 | < 0.001 | 2.2 | 1.8–2.8 | < 0.001 |
| R561H | 36 | 310 | 2.2 | 1.9–2.5 | < 0.001 | 2.2 | 1.9–2.6 | < 0.001 |
| V568G | 5 | 127 | 2.7 | 1.8–4.1 | < 0.001 | 2.7 | 1.8–4.1 | < 0.001 |
| P574L | 48 | 739 | 1.8 | 1.6–2.0 | < 0.001 | 2.0 | 1.7–2.2 | < 0.001 |
| P574L*** | 35 | 723 | 1.8 | 1.6–2.1 | < 0.001 | 1.8 | 1.6–2.1 | < 0.001 |
| C580Y | 450 | 997 | 2.2 | 2.1–2.4 | < 0.001 | 2.3 | 2.1–2.4 | < 0.001 |
| P667T**** | 5 | 50 | 2.2 | 1.6–2.9 | < 0.001 | 2.1 | 1.6–2.9 | < 0.001 |
| A675V | 49 | 501 | 2.2 | 1.9–2.4 | < 0.001 | 2.2 | 2.0–2.4 | < 0.001 |
1Adjusted for total artemisinin derivative dose in the first 3 days, partner drug, initial parasitemia and patient age
*20 P527H, one P527L, analyzed together, two P527H not analyzed since clearance data did not meet criteria
**With study ID 8, study site ID 23 (Tra Lang) removed
***With study ID 13, study site ID 15 (Pyin Oo Lwin) removed
****5 P667T, one P667T not analyzed since clearance data did not meet criteria